import img1 from "../../images/pillars_1.png";
import img2 from "../../images/pillars_2.jpg";
import img3 from "../../images/pillars_3.jpeg";
import img4 from "../../images/pillars_4.png";
import img5 from "../../images/pillars_5.png";
import img6 from "../../images/pillars_6.png";

export const dataPillars = [
  {
    id: 0,
    header: `1. Detection and Diagnosis - "Newborn Screening"`,
    description: `Detection and diagnosis is performed by Drugsintel's orphan prevalence software, which provides the biggest orphan 
    drug prevalence data in the world together with a smart machine learning and AI prediction tool. DrugsIntel detects and 
    collects genetic testing data for newborn babies and pregnant women to better identify rare disease patients as early as 
    possible. Cross-matching various diagnostic techniques, solutions, and their successful implementation in relevant clinics 
    holds great value. The activity is digitalized and automated, in order to maximize user experience.`,
    image: img1,
    subHeader: `Newborn Screening`,
    subDescription: [
      "- This strategy has the potential to achieve early diagnosis of rare diseases and apply mitigation interventions that can save and/or prolong lives if provided early enough in the process.",
      "- Multiple conditions can be identified from a single bloodspot data collected at birth.",
    ],
  },
  {
    id: 1,
    header: `2. Treatment access incentives and reimbursement`,
    description: `DrugsIntel today provides robust data on reimbursement and incentives of various rare diseases by country and globally. The collected data provide important information at a glance, with trends and clusters as a support to business decisions. Automatic screening of treatment access availability will be applied through the engagement of unique data sources providing robust information. The data are territory-related in order to better understand patterns and patient distributions.`,
    image: img2,
  },
  {
    id: 2,
    header: `3. Key opinion leader and healthcare professional collaboration`,
    description: `DI team of analysts use different engagement tools to identify KOL and HCP. Combining various platforms gauge valuable information on the two groups (mainly KOL). Leveraging the platforms, ensure laser focus reach to the most important leading physicians and researchers for a given orphan disease.`,
    image: img3,
  },
  {
    id: 3,
    header: `4. Treatment retention and collection of real-world data`,
    description: `Our Team of Experts continuously monitor and collect Real-World Data that provide meaningful insight which can be impactful to the KOL, HCP and pharmaceutical companies education. This activity can directly contribute to the orphan products acceptance and sales prediction. Using numerous validated sources, consisting of clinical trials data, healthcare websites and blogs, together with DrugsIntel's unique NLP algorithm can result in meaningful outcomes. Making sure to engage in the patient journey by applying a patient-centric approach, can systematically improve the treatment outcomes.`,
    image: img4,
  },
  {
    id: 4,
    header: `5. Advocacy group alliances`,
    description: `DrugsIntel is building a database silo containing the vast majority of advocacy groups, cascaded by their importance to a certain disease. Having a live stream communication with those organization, following their conferences and special disease days can contribute to the overall orphan disease coverage. Additionally, collaboration which include data sharing, KOL & patients communication, can result in impactable outcomes.`,
    image: img5,
  },
  {
    id: 5,
    header: `6. Disease awareness and education`,
    description: `Using various technological tools, to better evaluate and position a given orphan disease. Our specialized, qualified team of experts will perform a full education and awareness plan to communicate the disease to the relevant care givers and stakeholders with an aim to constantly enlarge the solution outreach. Advocating the disease awareness and education can result in more patients diagnosed or aware of their own or beloved ones disorder. It takes about 7 years and approximately 10 different wrong diagnoses to reach an optimal diagnosis. Suffering from an orphan condition can be debilitating. Building communities and knowledge around the disorder can contribute to an investment in research and development and pressure on governments to provide incentives and reimburse certain orphan diseases.`,
    image: img6,
  },
];
